Latest news

Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 Robust patient enrollment continues in confirmatory trial Surabgene lomparvovec

ROCKVILLE, Md., March 4, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Orlando, FL  

ROCKVILLE, Md., March 2, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Fireside Chat: Monday, March 9 at 9:20am ET Location: Miami, FL Barclays 28th Annual Global Healthcare

Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas

REGENXBIO

Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil